These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38851275)

  • 1. Finding Multiple Signals in the Noise: Handling Multiplicity in Clinical Trials.
    Chowdhry AK; Park J; Kang J; Sakthivel G; Pugh S
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):750-755. PubMed ID: 38851275
    [No Abstract]   [Full Text] [Related]  

  • 2. [Multiplicity of inferences in clinical trials: adjustment methods, clinical interpretation issues].
    Jouan-Flahault C; Casset-Semanaz F; Minini P
    Med Sci (Paris); 2004 Feb; 20(2):231-5. PubMed ID: 14997445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical planning to address strongly correlated endpoints for inferential subgroups: An innovative approach for an illustrative clinical trial with complex multiplicity issues.
    Sun H; Binkowitz B; Koch GG
    J Biopharm Stat; 2017; 27(3):399-415. PubMed ID: 28267412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the need to adjust for multiplicity in confirmatory clinical trials with master protocols.
    Stallard N; Todd S; Parashar D; Kimani PK; Renfro LA
    Ann Oncol; 2019 Apr; 30(4):506-509. PubMed ID: 30715156
    [No Abstract]   [Full Text] [Related]  

  • 5. Traditional multiplicity adjustment methods in clinical trials.
    Dmitrienko A; D'Agostino R
    Stat Med; 2013 Dec; 32(29):5172-218. PubMed ID: 24114861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical planning in confirmatory clinical trials with multiple treatment groups, multiple visits, and multiple endpoints.
    Sun H; Snyder E; Koch GG
    J Biopharm Stat; 2018; 28(1):189-211. PubMed ID: 28992425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for handling missing values in clinical trials.
    Little RJ
    J Rheumatol; 1999 Aug; 26(8):1654-6. PubMed ID: 10451057
    [No Abstract]   [Full Text] [Related]  

  • 8. Overview of multiple testing methodology and recent development in clinical trials.
    Wang D; Li Y; Wang X; Liu X; Fu B; Lin Y; Larsen L; Offen W
    Contemp Clin Trials; 2015 Nov; 45(Pt A):13-20. PubMed ID: 26210511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplicity adjustment big and small in clinical studies.
    Hsu JC
    Clin Pharmacol Ther; 2010 Aug; 88(2):251-4. PubMed ID: 20592727
    [No Abstract]   [Full Text] [Related]  

  • 10. Handling of Missing Data.
    Budhiraja P; Kaplan B; Mustafa RA
    Transplantation; 2020 Jan; 104(1):24-26. PubMed ID: 31365474
    [No Abstract]   [Full Text] [Related]  

  • 11. An introduction to multiplicity issues in clinical trials: the what, why, when and how.
    Li G; Taljaard M; Van den Heuvel ER; Levine MA; Cook DJ; Wells GA; Devereaux PJ; Thabane L
    Int J Epidemiol; 2017 Apr; 46(2):746-755. PubMed ID: 28025257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroups: time to go back to basic statistical principles?
    Keene ON; Garrett AD
    J Biopharm Stat; 2014; 24(1):58-71. PubMed ID: 24392978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple secondary outcome analyses: precise interpretation is important.
    Parker RA; Weir CJ
    Trials; 2022 Jan; 23(1):27. PubMed ID: 35012627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials.
    Collignon O; Gartner C; Haidich AB; James Hemmings R; Hofner B; Pétavy F; Posch M; Rantell K; Roes K; Schiel A
    Clin Pharmacol Ther; 2020 May; 107(5):1059-1067. PubMed ID: 32017052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of the limitations of statistical analysis of treatment outcomes used in periodontal research.
    Galgut PN
    J Int Acad Periodontol; 2003 Oct; 5(4):92-7. PubMed ID: 14604057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data handling in cancer clinical trials-how we can minimize potential biases.
    Sakamoto J; Teramukai S
    Jpn J Clin Oncol; 2002 Jan; 32(1):1-2. PubMed ID: 11932354
    [No Abstract]   [Full Text] [Related]  

  • 17. Non-adjustment for multiple testing in multi-arm trials of distinct treatments: Rationale and justification.
    Parker RA; Weir CJ
    Clin Trials; 2020 Oct; 17(5):562-566. PubMed ID: 32666813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatekeeping procedures with clinical trial applications.
    Dmitrienko A; Tamhane AC
    Pharm Stat; 2007; 6(3):171-80. PubMed ID: 17583553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):169-188. PubMed ID: 29125802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Traditional multiplicity problems.
    Paux G; Dmitrienko A
    J Biopharm Stat; 2018; 28(1):146-168. PubMed ID: 29172961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.